Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod
Executive Summary
Given the requirement for patients to have a Ki-67 score of at least 20%, the challenge now is to alter physicians’ thinking around Ki-67 testing, execs told Scrip.
You may also be interested in...
Veru Hopes To Position Enobosarm As Muscle-Protective In Weight-Loss Therapy
A selective androgen receptor modulator also being studied in metastatic breast cancer, enobosarm might offer potential as add-on therapy to GLP-1 agonists prescribed for weight loss, the Miami biotech asserts.
Earlier-Stage Approvals For Tecentriq, Keytruda, Verzenio Underscore Broader Oncology Trends
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
CDK4/6 Market: Is A Shakeup Underway?
Pfizer's Ibrance still dominates the category but sales slowed in the first quarter, while Novartis’s Kisqali and Lilly's Verzenio both grew double digits.